| The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and … AJ Palmer, S Roze, WJ Valentine, ME Minshall, V Foos, FM Lurati, ... Current medical research and opinion 20 (sup1), S5-S26, 2004 | 622 | 2004 |
| Validation of the CORE Diabetes Model against epidemiological and clinical studies AJ Palmera, S Rozea, WJ Valentinea, ME Minshallb, V Foosa, FM Luratia, ... Current Medical Research and Opinion 20 (sup1), S27-S40, 2004 | 356 | 2004 |
| Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting AJ Palmer, S Roze, WJ Valentine, P McEwan Diabetes care 30 (6), 1638, 2007 | 295* | 2007 |
| Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in … AJ Palmer, S Roze, WJ Valentine, GA Spinas, JE Shaw, PZ Zimmet Clinical therapeutics 26 (2), 304-321, 2004 | 189 | 2004 |
| Randomized trial of closed-loop control in very young children with type 1 diabetes J Ware, JM Allen, CK Boughton, ME Wilinska, S Hartnell, A Thankamony, ... New England Journal of Medicine 386 (3), 209-219, 2022 | 149 | 2022 |
| Health‐economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK S Roze, WJ Valentine, KE Zakrzewska, AJ Palmer Diabetic Medicine 22 (9), 1239-1245, 2005 | 129 | 2005 |
| Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe R Marty, S Roze, X Bresse, N Largeron, J Smith-Palmer BMC cancer 13, 1-12, 2013 | 124 | 2013 |
| Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and … AJ Palmer, L Annemans, S Roze, M Lamotte, P Lapuerta, R Chen, ... Diabetes Care 27 (8), 1897-1903, 2004 | 117 | 2004 |
| Cost‐effectiveness of diabetes case management for low‐income populations TP Gilmer, S Roze, WJ Valentine, K Emy‐Albrecht, JA Ray, D Cobden, ... Health services research 42 (5), 1943-1959, 2007 | 108 | 2007 |
| Cost‐effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review S Roze, J Smith‐Palmer, W Valentine, S de Portu, K Nørgaard, JC Pickup Diabetic Medicine 32 (11), 1415-1424, 2015 | 98 | 2015 |
| Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes JA Ray, KS Boye, N Yurgin, WJ Valentine, S Roze, J McKendrick, ... Current medical research and opinion 23 (3), 609-622, 2007 | 77 | 2007 |
| An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy … AJ Palmer, L Annemans, S Roze, M Lamotte, RA Rodby, DJ Cordonnier Nephrology Dialysis Transplantation 18 (10), 2059-2066, 2003 | 74 | 2003 |
| Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries AJ Palmer, WJ Valentine, S Roze, M Lammert, J Spiesser, S Gabriel Current medical research and opinion 21 (1), 19-26, 2005 | 73 | 2005 |
| The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy RA Rodby, CF Chiou, J Borenstein, A Smitten, N Sengupta, AJ Palmer, ... Clinical therapeutics 25 (7), 2102-2119, 2003 | 71 | 2003 |
| Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH WJ Valentine, AJ Palmer, KM Erny-Albrecht, JA Ray, D Cobden, V Foos, ... Advances in therapy 23, 191-207, 2006 | 67 | 2006 |
| Estimating the long‐term cost‐effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus ME Minshall, AK Oglesby, ME Wintle, WJ Valentine, S Roze, AJ Palmer Value in Health 11 (1), 22-33, 2008 | 63 | 2008 |
| Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis … AJ Palmer, S Roze, WJ Valentine, I Smith, KU Wittrup-Jensen Current medical research and opinion 20 (11), 1729-1746, 2004 | 62 | 2004 |
| Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective S Roze, J Smith-Palmer, WJ Valentine, M Cook, M Jethwa, S de Portu, ... Journal of medical economics 19 (3), 236-242, 2016 | 58 | 2016 |
| An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting AJ Palmer, L Annemans, S Roze, M Lamotte, RA Rodby, RW Bilous Journal of human hypertension 18 (10), 733-738, 2004 | 57 | 2004 |
| Health‐economic analysis of real‐time continuous glucose monitoring in people with Type 1 diabetes S Roze, R Saunders, AS Brandt, S De Portu, NL Papo, J Jendle Diabetic Medicine 32 (5), 618-626, 2015 | 56 | 2015 |
